These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2548774)

  • 21. Early detection of hepatoma in cirrhosis by serial quantitation of alpha-1-foetoprotein in serum.
    Niermeijer P; Gips CH; Marrink J; Qué GS
    Neth J Med; 1976; 19(1):15-8. PubMed ID: 55984
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma.
    Doğan UB; Cindoruk M; Dumlu S; Unlü R; Unal S
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):476-7. PubMed ID: 9494860
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary liver cell carcinoma and post-necrotic cirrhosis associated with Australia antigen and alpha-feto protein. (A case report).
    Malaviya AN; Nayak NC
    J Assoc Physicians India; 1971 Oct; 19(10):697-700. PubMed ID: 4332064
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma prekallikrein levels in patients with hepatocellular carcinoma and liver cirrhosis: a pilot study.
    Ciechanowicz A; Kawiak J; Miks B; Dutkiewicz T; Długosz A; Syczewska-Wawrzynowicz M; Marzecka J
    Ann Clin Biochem; 1993 Sep; 30 ( Pt 5)():445-8. PubMed ID: 8250496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus].
    Liu XE; Desmyter L; Gao CF; Laroy W; Dewaele S; Vanhooren V; Wang L; Zhuang H; Callewaert N; Libert C; Contreras R; Chen CY
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jan; 16(1):74-5. PubMed ID: 18226355
    [No Abstract]   [Full Text] [Related]  

  • 26. Emphysema, cirrhosis, and hepatoma with alpha-1 antitrypsin deficiency.
    Lieberman J
    Ann Intern Med; 1974 Dec; 81(6):850-2. PubMed ID: 4372921
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.
    Murawaki Y; Yamamoto H; Kawasaki H; Shima H
    Clin Chim Acta; 1993 Sep; 218(1):47-58. PubMed ID: 8299219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High levels of sterigmatocystin in patients with chronic liver diseases].
    Huţanaşu C; Sfarti C; Trifan A; Cojocariu C; Sîngeap AM; Spac A; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):33-7. PubMed ID: 21688557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA 50 serum levels in patients with liver diseases.
    Genolla J; Moragas G; Mañe S; Rosell M; Cuartero A; Encabo G; Ruibal A
    Int J Biol Markers; 1987; 2(3):207-8. PubMed ID: 2836527
    [No Abstract]   [Full Text] [Related]  

  • 30. Platelet Function: the Janus face of haemostasis in cirrhosis.
    Raparelli V; Basili S; Ferroni P
    Thromb Res; 2015 Jun; 135(6):1224-5. PubMed ID: 25910518
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis.
    Campello E; Zanetto A; Spiezia L; Radu CM; Gavasso S; Ferrarese A; Farinati F; Senzolo M; Simioni P
    Thromb Res; 2016 Jul; 143():118-21. PubMed ID: 27236709
    [No Abstract]   [Full Text] [Related]  

  • 32. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
    Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
    Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night.
    Wahlländer A; Mohr S; Paumgartner G
    J Hepatol; 1990 Mar; 10(2):129-37. PubMed ID: 2185297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selenium levels in patients with hepatitis C virus-related chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma: a pilot study.
    Bettinger D; Schultheiss M; Hennecke N; Panther E; Knüppel E; Blum HE; Thimme R; Spangenberg HC
    Hepatology; 2013 Jun; 57(6):2543-4. PubMed ID: 23172787
    [No Abstract]   [Full Text] [Related]  

  • 35. [Alpha-fetoprotein in relation to the age of the subject. Normal and pathological levels].
    Hurjui J; Teodorovici I; Creţeanu M
    Rev Med Chir Soc Med Nat Iasi; 1980; 84(2):283-6. PubMed ID: 6164085
    [No Abstract]   [Full Text] [Related]  

  • 36. [Immunochemical determination of alpha-fetoprotein in the dynamics of development of liver cirrhosis and hepatocellular cancer].
    Afanas'eva KA; Ragozin IuE; Tatarinov IuS
    Vestn Akad Med Nauk SSSR; 1975; (6):71-3. PubMed ID: 58499
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum lipids in hepatoma.
    Alsabti EA
    Oncology; 1979; 36(1):11-4. PubMed ID: 221872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography.
    Valero F; de la Torre R; Boobis AR; Murray S; Segura J
    J Pharm Biomed Anal; 1990; 8(8-12):783-7. PubMed ID: 2100623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombin III and hepatocellular carcinoma.
    Lefrère JJ; Conard J; Lerable J; Samama M
    Thromb Haemost; 1989 Sep; 62(2):817. PubMed ID: 2554522
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
    Mattera D; Capuano G; Colao A; Pivonello R; Manguso F; Puzziello A; D'Agostino L
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):699-706. PubMed ID: 14974910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.